New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Pfizer receives warning letter over EpiPen manufacturing; Opdivo kidney-cancer trial shows improved survival rates; cancer patients who discuss costs with physicians pay less
Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review
Insurers deny coverage of generic drugs; Teva to lay off 7,000 employees; Shkreli convicted of securities fraud
Cost of throwing out expired drugs is $800 million per year; the FDA approves Gilead's new HCV drug; CDC says 1 in 10 Americans have diabetes
The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision
To be sure, anything borrowing from the well-known "Keep Calm" genre should not be construed as advice. The doctor is definitely not in.
Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals
The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.